Thromboembolism - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Thromboembolism - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Thromboembolism - Pipeline Review, H1 2016', provides an overview of the Thromboembolism pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Thromboembolism
- The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects
- The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Thromboembolism

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Thromboembolism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Thromboembolism Overview 9
Therapeutics Development 10
Pipeline Products for Thromboembolism - Overview 10
Pipeline Products for Thromboembolism - Comparative Analysis 11
Thromboembolism - Therapeutics under Development by Companies 12
Thromboembolism - Therapeutics under Investigation by Universities/Institutes 13
Thromboembolism - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thromboembolism - Products under Development by Companies 17
Thromboembolism - Products under Investigation by Universities/Institutes 18
Thromboembolism - Companies Involved in Therapeutics Development 19
Bayer AG 19
Cereno Scientific AB 20
China Biologic Products, Inc. 21
Daiichi Sankyo Company, Limited 22
F. Hoffmann-La Roche Ltd. 23
Gamma Therapeutics, Inc. 24
GlycoMimetics, Inc. 25
Green Cross Corporation 26
Ionis Pharmaceuticals, Inc. 27
Portola Pharmaceuticals, Inc. 28
Sanofi 29
The International Biotechnology Center (IBC) Generium 30
Thromboembolism - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
alteplase biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
antithrombin III (human) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
betrixaban - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
C-3 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CS-1 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
edoxaban tosylate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Gammarin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GCC-2107 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GMI-1271 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ISIS-FXIRx - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Lysimab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Protein for Thromboembolism - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
rivaroxaban - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
semuloparin sodium - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
TAP-ANV - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
TRX-1 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
YG-001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Thromboembolism - Recent Pipeline Updates 66
Thromboembolism - Dormant Projects 89
Thromboembolism - Discontinued Products 90
Thromboembolism - Product Development Milestones 91
Featured News & Press Releases 91
Dec 07, 2015: First Data Unveiled from CALLISTO Program Examining the Use of XARELTO (rivaroxaban) for Treating Blood Clots in People with Cancer 91
Nov 30, 2015: New Data from Bayer's Portfolio in Thrombosis to be Presented at ASH 2015 93
Nov 06, 2015: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association Scientific Sessions 2015 93
Oct 30, 2015: Portola Pharmaceuticals Completes Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Prevention of Blood Clots in Acute Medically IllPatients 96
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis 97
Oct 13, 2015: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients 97
Sep 24, 2015: Bayer's Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis 98
Sep 24, 2015: Bayer's Xarelto Approved in Japan for the Treatment and Secondary Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis 99
Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots 99
Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer 100
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 102
Disclaimer 103

List of Tables

Number of Products under Development for Thromboembolism, H1 2016 10
Number of Products under Development for Thromboembolism - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Thromboembolism - Pipeline by Bayer AG, H1 2016 19
Thromboembolism - Pipeline by Cereno Scientific AB, H1 2016 20
Thromboembolism - Pipeline by China Biologic Products, Inc., H1 2016 21
Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 22
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 23
Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H1 2016 24
Thromboembolism - Pipeline by GlycoMimetics, Inc., H1 2016 25
Thromboembolism - Pipeline by Green Cross Corporation, H1 2016 26
Thromboembolism - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 27
Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 28
Thromboembolism - Pipeline by Sanofi, H1 2016 29
Thromboembolism - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 30
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Thromboembolism Therapeutics - Recent Pipeline Updates, H1 2016 66
Thromboembolism - Dormant Projects, H1 2016 89
Thromboembolism - Discontinued Products, H1 2016 90